Skip to main content
Fig. 6 | Clinical Sarcoma Research

Fig. 6

From: Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis

Fig. 6

One way sensitivity analysis evaluating incremental cost effectiveness ratios (ICERs) of CIUP compared with UAPR for a range of costs of imatinib. For all values of imatinib price, no meaningful ICER is accrued. In the setting of the known finding of CIUP having less effectiveness, this suggests that it is the more costly strategy overall regardless of imatinib cost

Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329